17:10 – 18:30
4 presentazioni orali selezionate dagli abstract.
The cell-permeable JNK inhibitor peptide (D-JNKI1) prevents motor defects and preserves dendritic spines in Mecp2 and CDKL5 mice models.
Sara Cimini, Eleonora Calcagno, Annamaria Castaldo, Grazia Della Sala, Elena Putignano, Tommaso Pizzorusso, Maurizio Giustetto e Tiziana Borsello
Pharmacological treatment with Mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice.
Tongiorgi Enrico; Bittolo Tamara, Raminelli Carlo Antonio, Deiana Chiara, Baj Gabriele, Vaghi Valentina, Ferrazzo Sara, Bernareggi Annalisa
MECP2 gene therapy for Rett syndrome: adding regulation.
Ralph D. Hector, Andrew McCracken, Mark E.S. Bailey, Stuart R. Cobb
Evaluating the effect of new readthrough drugs using a novel in vitro Rett Syndrome system, human neural cells carrying MeCP2 nonsense mutations.
Bruria Ben-Zeev, Andreea Nissenkorn, Timor Baasov, Meytal Shohat, Rinat Sack, Shmuel Tuvia and Chaya Brodie
Moderatori – Laviola G., Renieri A.
ABSTRACT
Autori:
Sara Cimini, Eleonora Calcagno, Annamaria Castaldo, Grazia Della Sala, Elena Putignano, Tommaso Pizzorusso, Maurizio Giustetto e Tiziana Borsello
Autori:
Tongiorgi Enrico; Bittolo Tamara, Raminelli Carlo Antonio, Deiana Chiara, Baj Gabriele, Vaghi Valentina, Ferrazzo Sara, Bernareggi Annalisa
Autori:
Ralph D. Hector, Andrew McCracken, Mark E.S. Bailey, Stuart R. Cobb
Autori:
Bruria Ben-Zeev, Andreea Nissenkorn, Timor Baasov, Meytal Shohat, Rinat Sack, Shmuel Tuvia and Chaya Brodie